Overview of Malanil

Quick Facts

Property	Description
Active ingredient	Atovaquone, Proguanil Hydrochloride
Form	Film-coated tablet (standard and pediatric)
Pharmacological class	Antimalarial, Antiprotozoal
Common purpose	Control and prevention of parasitic infection
Origin	Synthetic compound

What is Malanil: A Definition and Pharmacological Class

Malanil (also commercially known as Malarone) is a prescription-only medicine that is classified within the antimalarial and antiprotozoal pharmacological groups. It is specifically formulated as a fixed-dose combination product intended for oral administration. This combination is widely used in areas where drug-resistant Plasmodium falciparum malaria is reported.

This formulation is used in travel medicine and clinical practice because it utilizes two distinct synthetic compound active ingredients to provide a potent, synergistic defense. Malanil Pediatric Tablets represent a specific differentiating feature, offering an adjusted strength of the same dual agents specifically formulated for children. The drug acts as both a blood schizonticide and has causal prophylactic activity.

Composition and Therapeutic Rationale

The core therapeutic components of Malanil are the active ingredients, Atovaquone and Proguanil Hydrochloride (INN). The medicine is delivered as a film-coated tablet, a dosage form designed for controlled consumption.

The rationale behind the formulation is the synergistic effect achieved by combining the two agents. Atovaquone disrupts the parasite's essential energy pathway, while Proguanil is converted to its active metabolite, Cycloguanil, which prevents the parasite from synthesizing necessary DNA components. In clinical practice, this combination strategy helps ensure that the medicine remains effective even against strains that have developed resistance to older agents. The ultimate purpose of this fixed combination is to achieve both rapid control and sustained disruption of the parasite's life cycle, a key advantage when used by non-immune travelers.

Regulatory References

NIH/MedlinePlus on Atovaquone/Proguanil

What side effects are possible with Malanil?

Possible Side Effects and Safety Information

The safety characteristics of Malanil (Atovaquone/Proguanil) are comprehensively documented by governmental regulatory authorities (such as the EMA and FDA), which classify adverse reactions based on their frequency of occurrence in clinical use.

Adverse effects are grouped into categories that include Very Common, Common, Uncommon, and Rare events, as well as those reported post-marketing with Frequency Not Known.

Frequency-Classified Adverse Reactions

The most frequently documented side effects are classified as Very Common, occurring in more than 1 in 10 patients. These often include headache and disturbances within the Gastrointestinal system, such as abdominal pain, nausea, vomiting, and diarrhoea.

Common reactions, documented in less than 1 in 10 but more than 1 in 100 patients, involve other systems, including Insomnia, dizziness, and some Psychiatric disorders like depression and abnormal dreams. Elevated liver enzyme levels are also classified as common.

Serious Safety Considerations

Official labeling documents address clinically significant, less frequent reactions, including those from post-marketing surveillance, which are considered Serious Adverse Reactions. These include reports of severe hypersensitivity reactions such as Anaphylaxis and Angioedema, as well as severe skin disorders like Stevens-Johnson syndrome (SJS). Cases of severe Hepatotoxicity, including Hepatitis and Hepatic failure, have also been reported.

Population-Specific and Use Restrictions

Safety constraints formalized in regulatory documents include a contraindication for the prophylaxis of malaria in individuals with severe renal impairment (Creatinine clearance less than 30 mL/min). Furthermore, the medicine is generally not recommended during pregnancy or lactation. Side effects are generally reported as more pronounced when the medicine is used at the higher treatment doses compared to the lower prophylactic doses.

Overdose and Emergency Response

Overdose Scope

Feature	Official Regulatory Statement
Documented Overdose Presentations	Manifestations observed are primarily linked to the proguanil component, including reports of acute renal failure and hematological changes. Acute atovaquone overdose experience is limited.
Physiological Systems Affected (as stated in label)	Renal system (potential for acute renal failure) and the hematological system.
Dose-related or Exposure-related Factors (if applicable)	Overdose risk is associated with exposure to quantities substantially higher than the recommended dose.
Population-specific Overdose Notes (if applicable)	Official labeling does not detail unique symptom manifestations based on age or underlying condition; general emergency management is applied universally.
Emergency-response statements (as written in official documents)	Treatment is symptomatic and supportive. Administration of activated charcoal or gastric lavage may be considered.
When immediate medical help is required (label-derived phrasing only)	Seek immediate medical attention for any suspected overdose. Emergency medical care and hospital monitoring are required.

Overdose Classifications (High-Level)

Classification	Official Regulatory Statement
Severity Classification (as defined in official documents)	Associated with the potential for severe outcomes, including acute renal failure.
Regulatory Basis (EMA / FDA / etc.)	Based on official labeling information from regulatory authorities such as the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) Summaries of Product Characteristics (SmPC).
Overdose-context constraints (as defined in official documents)	No specific antidote is known.

Resulting Overdose Structure

Official Overdose Statements:

A suspected overdose of Malanil mandates that the user seek immediate medical attention.
Regulatory documents associate overdose with the potential for severe adverse events, specifically acute renal failure and hematological changes, primarily linked to the proguanil component.
No specific antidote is known for this fixed-dose combination; therefore, mandated treatment is symptomatic and supportive.
Hospital monitoring is necessary, with a focus on assessing renal function due to the identified risks, and medical intervention may involve procedural steps such as gastric lavage or activated charcoal.

Connection to the overall overdose profile (3 sentences): Regulatory documents define the overdose profile by listing specific severe events and immediately mandating immediate medical attention to manage these risks. The lack of a specific antidote shifts the regulatory focus to symptomatic and supportive treatment, including the requirement for hospital monitoring to assess the renal and hematological systems. This structure strictly guides the required emergency response based on documented toxicological findings.

Therapeutic Uses of Malanil

Malanil is commonly used for managing and preventing infection by the Plasmodium falciparum parasite, particularly in settings where drug resistance is a known challenge. Its role is to help address active infection and contribute to preventing the disease.

The primary indication is for the prevention of malaria, alongside its use in the treatment of acute, uncomplicated P. falciparum infection. The medicine is applied in addressing both these clinical needs. The benefit contributes to resolving the acute illness, helping ease the overall symptom load, and supports the patient during difficult episodes by easing distress.

Treatment and Symptom Management

Malanil is relevant for easing symptoms related to systemic imbalance in acute cases, including high and cyclical fever, generalized chills and rigors, intense headache, and profound malaise. The medication is also commonly used in chemoprophylaxis for non-immune travelers to contribute to preventing the onset of symptoms.

“This medication is key in contexts involving parasitic infection and is relevant when supportive symptom management is appropriate.”

Symptom Focus: Systemic Febrile Distress

Patient Benefits and Clinical Context

This therapeutic domain covers two critical clinical scenarios: the resolution of an active parasitic illness, and the provision of effective protection for non-immune individuals exposed to the parasite. By helping to control the parasitic load, Malanil supports a more manageable experience of day-to-day functioning, contributing to preventing the onset of symptoms and assisting with maintaining functional stability.

Quick Fact: Supports managing the systemic symptoms associated with uncomplicated P. falciparum infection and is relevant for prevention in high-risk travel contexts.

Eligibility and Restrictions for Use

Malanil is intended for use only in specific populations as defined by regulatory labeling.

Who Must Not Use Malanil

Malanil is contraindicated in individuals with a known history of serious hypersensitivity reactions to atovaquone, proguanil hydrochloride, or any formulation component. Use is also strictly contraindicated for malaria prevention (prophylaxis) in patients diagnosed with severe renal impairment (creatinine clearance less than 30 mL/ min).

Age and Condition Restrictions

The medicine is approved for the treatment of uncomplicated malaria in children weighing 5 kilograms and above. For prophylaxis, eligibility thresholds are typically 11 kilograms for the pediatric formulation. Use is not recommended for women who are breastfeeding, and safety has not been established during pregnancy. Caution is required when administering Malanil for treatment in patients with severe renal impairment or those with existing hepatic impairment. Furthermore, the oral formulation has not been evaluated for use in patients with severe or complicated forms of malaria, such as cerebral malaria.

What should I know about interactions with other medicines?

Interaction Map: Interactions with other medicines and products — official regulatory information for Malanil

Category	Official Regulatory Documentation Summary
Medicinal product categories with documented interactions	Anticoagulants (Coumarin-based), certain Anti-tuberculosis agents, antiemetics, and certain HIV antivirals.
Specific interacting medicines (if explicitly listed)	Rifampin, Rifabutin, Tetracycline, Metoclopramide, Warfarin, Indinavir.
Mechanistic basis of interactions (only if stated in label)	Pharmacokinetic interaction (resulting in reduced plasma concentration of atovaquone); Pharmacodynamic interaction (resulting in alteration of coagulation); Proguanil metabolism via CYP2C19.
Timing-based interaction rules (if applicable)	No mandatory time separation rules are explicitly documented in primary regulatory labels.
Population-specific interaction notes (if applicable)	Severe renal impairment (creatinine clearance less than 30 mL/ min) prolongs half-lives and may cause accumulation of proguanil and cycloguanil.
Interaction-related restrictions	Co-administration with Rifampin or Rifabutin is not recommended due to significant reduction in atovaquone plasma concentrations.

Interaction Classifications (High-Level)

Category	Official Regulatory Statement
Interaction severity classification (as defined in official documents)	Contraindicated (for prophylaxis in severe renal impairment); Not Recommended (with Rifampin/Rifabutin); Requires Monitoring (with Warfarin/Tetracycline).
Regulatory basis (EMA / FDA / etc.)	Drug label information from regulatory agencies including the U.S. Food and Drug Administration.
Interaction-context constraints (as defined in official documents)	Administration with food or a milky drink is required to enhance atovaquone absorption; Diarrhea or vomiting may reduce atovaquone absorption, requiring close monitoring of outcomes.

Official interaction statements:

Rifampin and Rifabutin co-administration is not recommended as this pharmacokinetic interaction causes a significant reduction in atovaquone plasma levels.
The proguanil component may potentiate the effect of Coumarin-based Anticoagulants (e.g., Warfarin), requiring close monitoring of coagulation tests when Malanil is started or discontinued.
Use for prophylaxis is contraindicated in individuals with severe renal impairment due to the potential for the accumulation and prolonged half-life of proguanil and its active metabolite.
Co-treatment with agents such as Tetracycline and Metoclopramide may decrease atovaquone exposure and require increased attention to therapeutic response.

Connection to the overall interaction profile (2–4 sentences): Official regulatory documents define Malanil's interaction structure around pharmacokinetic constraints, highlighting significant reductions in drug exposure when combined with certain anti-infectives. This profile establishes mandatory co-administration restrictions, mandates procedural monitoring (e.g., for anticoagulation), and strictly prohibits use for prophylaxis in the presence of specific population conditions where accumulation risk is documented.

Mechanism of Action

The pharmacological effect of Malanil involves the coordinated blockade of two separate, essential metabolic pathways within the Plasmodium parasite, thereby affecting DNA replication and maturation.

Targeting Parasite Bioenergetics (Atovaquone)

This mechanism begins with Atovaquone acting as a competitive inhibitor of the parasite’s Mitochondrial Cytochrome bc1 complex ( Complex III), specifically blocking the electron transport chain ( mtETC) at the ubiquinol binding site. This rapid blockade collapses the parasite’s mitochondrial membrane potential (DeltaPsim) and starves the DHODH enzyme, functionally arresting the synthesis of necessary pyrimidine precursors for DNA replication.

Inhibiting Folate and Nucleic Acid Synthesis (Cycloguanil)

The second mechanism involves the Proguanil metabolite, Cycloguanil, which inhibits the parasite's dihydrofolate reductase ( DHFR) enzyme. By blocking DHFR, Cycloguanil prevents the regeneration of tetrahydrofolate, a required co-factor for synthesizing purines and other DNA components. This parallel blockade deprives the parasite of DNA building blocks, leading to a failure to replicate genetic material.

Synergistic Dual-Pathway Blockade

The combination strategy results in amplified parasiticidal pressure: Proguanil itself acts as a mitochondrial sensitizer, amplifying the Atovaquone effect, while the dual molecular targets ( mtETC and DHFR) create a high barrier against parasitic resistance. This dual-point attack contributes to the cessation of nuclear division and growth in both the asexual blood stage and the liver stage. This synergistic inhibition of nuclear division affects the parasite’s ability to multiply within the host.

Dosage and Administration Information

Malanil is an oral medication administered as a fixed-dose combination, film-coated tablet. The medicine must be taken once daily, and its proper use is intrinsically tied to food intake. The tablet should be ingested with food or a milky drink to ensure appropriate absorption of the active ingredients.

The administration protocol differs based on the indication. For prophylaxis, the standard adult dose is one tablet daily, which must be initiated one or two days prior to entering the malaria-endemic area. Dosing continues daily during the stay and for seven full days after leaving the area. For the treatment of acute, uncomplicated infection, the standard adult regimen is four tablets taken once daily for a course of only three consecutive days.

Administration Guidelines

Feature	Official Usage Instruction
Route of Administration	Oral, as a film-coated tablet.
Food Dependency	Must be taken with food or a milky drink.
Swallowing Difficulty	Tablets may be crushed and mixed with condensed milk immediately before administration.
Dose Repeat	If vomiting occurs within one hour of a dose, a repeat dose is required.

Population-Specific Constraints

Dosing in pediatric patients is highly specific, based on body weight rather than age. Use is formally restricted by renal function: Malanil is contraindicated for prophylaxis in patients with severe renal impairment (creatinine clearance <30 mL/ min). The complete official use protocol is time-sensitive and requires consistent daily administration for the entire duration defined by the product guidance.

Recent Clinical Evidence

Malanil: Recent Clinical Evidence

Research has explored the use of Malanil (Atovaquone/Proguanil) for two primary indications: malaria prophylaxis and acute malaria infection. Studies were observed in clinical contexts to understand data show patterns related to the medicine was studied for these specific settings.

1. Evidence for Malaria Prophylaxis

The evidence for prophylaxis primarily comes from short-term Randomized Controlled Trials (RCTs) and systematic reviews. These studies were evaluated in populations including non-immune adult travelers and pediatric travelers, with research observing responses over defined time intervals. The outcomes that research examined included the measurement of parasite infection. Studies observed the incidence of clinical malaria episodes when compared to placebo groups. Research exploring short-term symptom changes was observed in some studies when evaluated against other prophylactic agents.

**2. Evidence for Acute, Uncomplicated P. falciparum Infection**

Malanil was studied for its use in managing acute, uncomplicated infection caused by the Plasmodium falciparum parasite. The research focuses on settings where the parasite may have resistance to older medicines. The research base includes controlled studies evaluated in patients with a confirmed acute infection, including adults and pediatric patients. The primary scientific endpoint research examined in these treatment trials relates to the rate of parasite clearance and the reported incidence of treatment failure. Findings describe patterns observed in the studies related to rates of clearance in the observed populations.

3. Research Gaps and Areas of Uncertainty

While the research describes patterns for the studied indications, evidence highlights what is known—and what is still uncertain. The evidence for outcomes primarily focuses on P. falciparum. Research findings on the use against infections caused by other species (e.g., P. vivax and P. ovale) are not as well-documented. Furthermore, long-term effects are not fully established, and consistent outcome data for use extending beyond a few weeks are limited, as noted in observational studies on non-immune travelers.

Frequently Asked Questions (FAQ)

Common questions about Malanil (FAQ)

Q: What is Malanil prescribed for?

Regulatory documents state that this medication is indicated for the prophylaxis (prevention) of malaria caused by the Plasmodium falciparum parasite. It is also used for the treatment of acute, uncomplicated malaria caused by the same parasite.

Q: Is Malanil the same type of medicine as other drugs used for the same condition?

Malanil is a fixed-dose combination of two active ingredients, Atovaquone and Proguanil. These ingredients work together through a dual-action mechanism, simultaneously targeting two separate, essential metabolic pathways within the malaria parasite.

Q: Is Malanil available over-the-counter?

The official documentation published by regulatory bodies is the Prescribing Information, which indicates the drug is available only by prescription from a healthcare provider.

Q: What are the most common side effects people notice with Malanil?

According to official clinical trial data, common reactions reported by adults taking the drug for prevention included diarrhea, strange dreams, oral ulcers, and headache. In children, common reactions included abdominal pain, headache, cough, and vomiting.

Q: How quickly does Malanil typically start working?

For the purpose of preventing malaria, official guidelines describe starting the medication one or two days before traveling to an area where malaria is common. This protocol ensures the active ingredients are present in the body before potential exposure.

Q: Does Malanil have a warning about drowsiness or driving?

Official post-marketing reports include nervous system effects such as dizziness and vertigo. Rare cases of seizures and psychotic events have also been reported. These central nervous system effects are the types of reactions that may impact coordination and driving ability.

Q: Can you take Malanil with blood pressure medication?

Official drug information warns that the medication has known interactions with many other drugs. Official documents describe the need for a healthcare provider to review a complete list of all current medications to check for potential interactions.

Q: What kind of studies have been done on Malanil?

Regulatory literature includes information about clinical studies that have examined the drug’s effectiveness and overall safety profile. These trials specifically focused on both the prevention and the treatment of uncomplicated P. falciparum malaria.

Q: Are there any long-term effects associated with using Malanil?

This medication is generally intended for short-term use (for prophylaxis or a short treatment course). Post-marketing reports have included rare cases of serious effects like elevated liver tests, hepatitis, and hepatic failure (severe liver damage), which are events that may require clinical follow-up.

Q: Who should not use Malanil, based on official information?

Official information states the drug is contraindicated (should not be used) in individuals with a known severe hypersensitivity reaction (a serious allergic response) to either active ingredient. It is also contraindicated for prevention in patients with severe renal impairment (kidney function problems).

Q: Is Malanil safe to take during pregnancy, according to official sources?

Official regulatory sources indicate there is currently insufficient data to determine the drug-associated risk for adverse outcomes during pregnancy. The lack of sufficient human data is a key factor in decisions regarding use during pregnancy.

Q: What are the concerns about Malanil and breastfeeding?

Official guidelines include a constraint against use by women who are breastfeeding infants who weigh less than 5 kg. This constraint is due to limited information on the extent of drug exposure in very small nursing infants.

Q: Does Malanil interact with alcohol consumption?

Official drug interaction profiles indicate a possible interaction with alcohol, a factor which is considered in the prescribing decision.

Q: Can Malanil be used by children?

Yes, official information describes dosing protocols for children. The drug is indicated for use in children who weigh at least 11 pounds (5 kg). The dosage prescribed is highly specific and is based on the child’s body weight.

Q: Are there specific food restrictions while taking Malanil?

Regulatory documents describe the use condition as being taken with food or a milky drink to ensure appropriate absorption of the active ingredients. No specific foods are restricted beyond general warnings about alcohol and supplements.

Q: Is Malanil known to cause weight gain or loss?

Based on the official clinical trial data reported to regulatory bodies, weight change is not listed among the commonly reported side effects of the medication.

Q: Why do some people experience stomach upset with Malanil?

Gastrointestinal problems are a commonly reported adverse reaction, especially at the higher doses used for treatment. The regulatory documents list stomach upset side effects, including abdominal pain, nausea, and vomiting.

Q: What happens if Malanil is taken with certain supplements?

Official patient guidance describes the requirement to inform the healthcare professional of all concomitant products, including herbal and dietary supplements, due to the potential for drug-supplement interactions.

Q: How does the official literature describe Malanil's effectiveness?

The drug is described as effective for its indicated use, which includes the treatment of acute, uncomplicated P. falciparum malaria. It is considered effective even in regions where the malaria parasite has developed resistance to some older antimalarial drugs.

Q: What are the official recommendations for storing Malanil tablets?

The official Prescribing Information includes a specific section detailing the recommended storage temperature and handling conditions for the tablets. These instructions describe the conditions necessary to maintain the integrity of the medicine.

Q: Can Malanil affect lab test results?

Yes, regulatory reporting includes mentions of elevated liver laboratory tests as a possible adverse reaction. This indicates that the drug can potentially affect certain lab values related to liver function.

Q: Are there different strengths of Malanil available?

Yes, official regulatory information describes a standard adult-strength tablet and a separate pediatric-strength tablet. The concentration of the active ingredients differs between these two forms.

Q: Are Malanil's side effects common, rare, or serious?

The drug's overall safety profile is described as having generally mild side effects. However, the prescribing information categorizes both common reactions and lists rare but serious post-marketing events, such as hepatic failure and severe skin reactions.

Q: Can Malanil be used by older adults (seniors)?

The official Prescribing Information includes a specific section dedicated to Geriatric Use. This section contains safety and dosing considerations relevant to older adults.

Q: Does Malanil affect sleep patterns?

Yes, the official adverse reactions list includes effects on sleep. Both clinical trial data and post-marketing reports specifically list insomnia and strange or vivid dreams as reported side effects.

Q: What should I do if I think I'm having a serious side effect from Malanil?

Official documents describe the procedure for reporting severe reactions, including the need for immediate medical attention for emergency situations and the process for reporting suspected adverse reactions to the FDA MedWatch program.

Q: Does the package insert for Malanil list any rare but serious side effects?

Yes, the post-marketing surveillance section of the regulatory label includes reports of rare but serious effects. These include hepatic failure (liver failure), severe cutaneous adverse reactions (like Stevens-Johnson syndrome), and nervous system effects such as seizures.

Q: How is Malanil classified by government health agencies?

Government health agencies classify this medication as an antimalarial drug. Its indicated use is specific to the prevention and treatment of malaria caused by the Plasmodium falciparum parasite.

Q: Is it true that Malanil can cause sun sensitivity?

Yes, post-marketing reports have included skin reactions such as photosensitivity (increased sensitivity to the sun). Official guidance notes that due to the risk of photosensitivity, protection from the sun is a consideration while using the medication.

Q: What information is available about Malanil and liver health?

Official warnings note that adverse liver events are possible. These have included elevated liver laboratory tests, hepatitis, and hepatic failure (in rare cases requiring liver transplantation) reported with the preventative use of the medication.

Q: Do studies show Malanil works better for certain groups of people?

Clinical trials evaluate efficacy across various populations. Official pharmacokinetic data indicates that the metabolism of one active ingredient (Proguanil) can be variable in certain ethnic groups, which may influence drug exposure in those individuals.

Q: What are the limitations or uncertainties mentioned in the research on Malanil?

The prescribing information notes that the drug has not been evaluated for the treatment of cerebral malaria or other severe, complicated forms of the disease. Its approved uses are restricted to the prevention and treatment of uncomplicated malaria.

Q: If I have a chronic condition, can I still take Malanil?

Official warnings describe specific caution related to a history of certain chronic conditions. These include kidney problems, liver problems, or a history of seizures.

Q: Why do official documents state 'Do not stop taking Malanil suddenly'?

The drug’s use protocol is time-sensitive and requires consistent daily administration for the entire prescribed duration. Stopping too soon, especially for treatment or prophylaxis, increases the risk of treatment failure or a relapse of the infection.

Q: How is the general safety profile of Malanil described?

The general safety profile is described as having mostly mild side effects, with more adverse reactions typically seen with the higher doses used for treatment compared to the lower doses used for prevention.

Q: What happens to the medicine in the body (pharmacokinetics) according to the leaflet?

The official document describes the drug’s pharmacokinetics (how the body handles the drug). Key details include that its absorption is highly dependent on food intake and that its metabolism into the active form occurs in the liver.

Q: Is Malanil known to interact with herbal remedies?

Official patient guidance describes the requirement to inform the healthcare professional of all concomitant products, which specifically includes herbal remedies.

Q: Can Malanil affect fertility in men or women?

The prescribing information contains sections addressing potential effects on fertility based on animal studies. Separate sections in the regulatory documents also provide information on use during pregnancy and lactation.

How should Malanil be stored and disposed of?

Storage and Disposal of Malanil

Malanil (atovaquone and proguanil hydrochloride) tablets must be stored according to official regulatory labeling to ensure product stability and safety.

Storage Requirements

Requirement	Condition
Temperature	Store below 30 C (86 F)
Protection	Keep in the original container, away from excess heat and moisture.
Child Safety	Keep all medication strictly out of the sight and reach of children.
Stability	The product has a labeled shelf life of 5 years when stored correctly.

Disposal Instructions

Unused or expired Malanil must not be disposed of in household trash or poured into wastewater. All waste material should be disposed of in accordance with local requirements. Most often, this involves returning the medication to a pharmacy or designated collection program for safe disposal.

Malanil